AnHeart is currently developing three precision oncology assets at various clinical stages.
Taletrectinib/AB-106 – Phase 2
a next-generation ROS1 inhibitor
ROS1 fusion-positive non-small cell lung cancer (NSCLC)
AB-218 – Phase 2
a mIDH1 inhibitor
Lower grade glioma, cholangiocarcinoma and other tumors
AB-329 – Phase 1
an AXL inhibitor
Combination therapy with checkpoint inhibitors or chemotherapy in NSCLC and other solid tumors
We are also advancing a number of preclinical precision oncology programs.
1. AnHeart out-licensed commercial rights in greater China to Innovent Biologics and in Korea to NewG Lab
2. Daiichi Sankyo keeps development and commercial rights in Japan
Taletrectinib / AB-106 (ROS1 inhibitor)
Taletrectinib is a novel best-in-class next-generation brain-penetrant ROS1 inhibitor which has demonstrated excellent potency against crizotinib resistance in tumors and has shown very good intracranial antitumor activity and a strong safety profile in ROS1 fusion-positive NSCLC patients.
AB-218 (mIDH1 inhibitor)
AB-218 is a brain-penetrant mIDH1 inhibitor for multiple solid tumors with IDH1 mutations.
AB-329 (AXL inhibitor)
AB-329 is a potent and selective AXL inhibitor that can potentially be used in combination with other therapies to overcome resistance in multiple solid tumors and hematological cancers.
